JAGUAR HEALTH, INC. Net Income
JAGUAR HEALTH, INC. (JAGX) reported Net Income of -$54.00 thousand for the 12-month period ending 2025-12-31, per its DEF 14A filed 2026-04-30.
Financial Statements › Income Statement › Net Income
us-gaap:NetIncomeLoss · last filed 2026-04-30
- JAGUAR HEALTH, INC. net income (loss) attributable to parent for the quarter ending 2025-12-31 was $30.32M, a 6.26% increase year-over-year.
- JAGUAR HEALTH, INC. net income (loss) attributable to parent for the quarter ending 2025-09-30 was -$9.50M.
- JAGUAR HEALTH, INC. net income (loss) attributable to parent for the quarter ending 2025-06-30 was -$10.41M.
- JAGUAR HEALTH, INC. net income (loss) attributable to parent for the quarter ending 2025-03-31 was -$10.46M.
- JAGUAR HEALTH, INC. net income (loss) attributable to parent for fiscal 2022 was -$48.40K.
- JAGUAR HEALTH, INC. net income (loss) attributable to parent for fiscal 2021 was -$52.60K.
- JAGUAR HEALTH, INC. net income (loss) attributable to parent for fiscal 2020 was -$33.81M.
- JAGUAR HEALTH, INC. net income (loss) attributable to parent for fiscal 2019 was -$38.54M.
| Period end | Net Income (Loss) Attributable to Parent 3 month | Net Income (Loss) Attributable to Parent 3 month as first filed | Net Income (Loss) Attributable to Parent 6 month | Net Income (Loss) Attributable to Parent 6 month as first filed | Net Income (Loss) Attributable to Parent 9 month | Net Income (Loss) Attributable to Parent 9 month as first filed | Net Income (Loss) Attributable to Parent 12 month | Net Income (Loss) Attributable to Parent 12 month as first filed |
|---|---|---|---|---|---|---|---|---|
| 2025-12-31 | $30.32M derived: DEF 14A 12 month − 10-Q 9 month · filed 2026-04-30 | $20.82M derived: sum of 2 quarters · filed 2026-04-30 | $10.41M derived: sum of 3 quarters · filed 2026-04-30 | -$54.00K DEF 14A · filed 2026-04-30 | -$53.58M 10-K · filed 2026-04-07 | |||
| 2025-09-30 | -$9.50M 10-Q · filed 2025-11-14 | -$19.91M derived: sum of 2 quarters · filed 2025-11-14 | -$30.37M 10-Q · filed 2025-11-14 | -$1.84M derived: sum of 4 quarters · filed 2026-04-30 | ||||
| 2025-06-30 | -$10.41M 10-Q · filed 2025-08-14 | -$20.87M 10-Q · filed 2025-08-14 | $7.66M derived: sum of 3 quarters · filed 2026-04-30 | -$2.19M derived: sum of 4 quarters · filed 2026-04-30 | ||||
| 2025-03-31 | -$10.46M 10-Q · filed 2025-05-15 | $18.07M derived: sum of 2 quarters · filed 2026-04-30 | $8.21M derived: sum of 3 quarters · filed 2026-04-30 | -$1.28M derived: sum of 4 quarters · filed 2026-04-30 | ||||
| 2024-12-31 | $28.53M derived: DEF 14A 12 month − 10-Q 9 month · filed 2026-04-30 | $18.68M derived: sum of 2 quarters · filed 2026-04-30 | $9.19M derived: sum of 3 quarters · filed 2026-04-30 | -$39.25K DEF 14A · filed 2026-04-30 | -$38.49M 10-K · filed 2025-03-31 | |||
| 2024-09-30 | -$9.85M 10-Q · filed 2025-11-14 | -$19.35M derived: sum of 2 quarters · filed 2025-11-14 | -$28.57M 10-Q · filed 2025-11-14 | $3.52M derived: sum of 4 quarters · filed 2026-04-30 | ||||
| 2024-06-30 | -$9.49M 10-Q · filed 2025-08-14 | -$18.72M 10-Q · filed 2025-08-14 | $13.37M derived: sum of 3 quarters · filed 2026-04-30 | $5.59M derived: sum of 4 quarters · filed 2026-04-30 | ||||
| 2024-03-31 | -$9.23M 10-Q · filed 2025-05-15 | $22.86M derived: sum of 2 quarters · filed 2026-04-30 | $15.08M derived: sum of 3 quarters · filed 2026-04-30 | $2.93M derived: sum of 4 quarters · filed 2026-04-30 | ||||
| 2023-12-31 | $32.09M derived: DEF 14A 12 month − 10-Q 9 month · filed 2026-04-30 | $24.31M derived: sum of 2 quarters · filed 2026-04-30 | $12.16M derived: sum of 3 quarters · filed 2026-04-30 | -$41.90K DEF 14A · filed 2026-04-30 | -$41.30M 10-K · filed 2024-04-01 | |||
| 2023-09-30 | -$7.78M 10-Q · filed 2024-11-13 | -$19.93M derived: sum of 2 quarters · filed 2024-11-13 | -$32.13M 10-Q · filed 2024-11-13 | $7.69M derived: sum of 4 quarters · filed 2025-04-15 | ||||
| 2023-06-30 | -$12.15M 10-Q · filed 2024-08-13 | -$24.35M 10-Q · filed 2024-08-13 | $15.47M derived: sum of 3 quarters · filed 2025-04-15 | $2.95M derived: sum of 4 quarters · filed 2025-04-15 | ||||
| 2023-03-31 | -$12.20M 10-Q · filed 2024-05-14 | $27.62M derived: sum of 2 quarters · filed 2025-04-15 | $15.10M derived: sum of 3 quarters · filed 2025-04-15 | $5.74M derived: sum of 4 quarters · filed 2025-04-15 | ||||
| 2022-12-31 | $39.82M derived: 10-K/A 12 month − 10-Q 9 month · filed 2025-04-15 | $27.30M derived: sum of 2 quarters · filed 2025-04-15 | $17.94M derived: sum of 3 quarters · filed 2025-04-15 | -$48.40K 10-K/A · filed 2025-04-15 | -$47.45M 10-K · filed 2024-04-01 | |||
| 2022-09-30 | -$12.52M 10-Q · filed 2023-11-14 | -$21.89M derived: sum of 2 quarters · filed 2023-11-14 | -$39.87M 10-Q · filed 2023-11-14 | -$1.64M derived: sum of 4 quarters · filed 2025-04-15 | ||||
| 2022-06-30 | -$9.37M 10-Q · filed 2023-08-14 | -$27.35M 10-Q · filed 2023-08-14 | $10.88M derived: sum of 3 quarters · filed 2025-04-15 | -$1.32M derived: sum of 4 quarters · filed 2025-04-15 | ||||
| 2022-03-31 | -$17.99M 10-Q · filed 2023-05-15 | $20.24M derived: sum of 2 quarters · filed 2025-04-15 | $8.05M derived: sum of 3 quarters · filed 2025-04-15 | -$6.03M derived: sum of 4 quarters · filed 2025-04-15 | ||||
| 2021-12-31 | $38.23M derived: 10-K/A 12 month − 10-Q 9 month · filed 2025-04-15 | $26.04M derived: sum of 2 quarters · filed 2025-04-15 | $11.96M derived: sum of 3 quarters · filed 2025-04-15 | -$52.60K 10-K/A · filed 2025-04-15 | ||||
| 2021-09-30 | -$12.19M 10-Q · filed 2021-11-17 | -$26.27M derived: sum of 2 quarters · filed 2021-11-17 | -$38.28M 10-Q · filed 2021-11-17 | -$47.05M derived: sum of 4 quarters · filed 2021-11-17 | ||||
| 2021-06-30 | -$14.08M 10-Q · filed 2021-08-13 | -$26.09M 10-Q · filed 2021-08-13 | -$34.86M derived: sum of 3 quarters · filed 2021-08-13 | -$42.73M derived: sum of 4 quarters · filed 2021-11-17 | ||||
| 2021-03-31 | -$12.01M 10-Q · filed 2021-05-17 | -$20.78M derived: sum of 2 quarters · filed 2021-05-17 | -$28.64M derived: sum of 3 quarters · filed 2021-11-17 | -$37.88M derived: sum of 4 quarters · filed 2021-11-17 | ||||
| 2020-12-31 | -$8.77M derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-31 | -$16.64M derived: sum of 2 quarters · filed 2021-11-17 | -$25.87M derived: sum of 3 quarters · filed 2021-11-17 | -$33.81M 10-K · filed 2021-03-31 | ||||
| 2020-09-30 | -$7.87M 10-Q · filed 2021-11-17 | -$17.10M derived: sum of 2 quarters · filed 2021-11-17 | -$25.04M 10-Q · filed 2021-11-17 | -$31.00M derived: sum of 4 quarters · filed 2021-11-17 | ||||
| 2020-06-30 | -$9.24M 10-Q · filed 2021-08-13 | -$17.17M 10-Q · filed 2021-08-13 | -$23.13M derived: sum of 3 quarters · filed 2021-08-13 | -$30.69M derived: sum of 4 quarters · filed 2021-08-13 | ||||
| 2020-03-31 | -$7.94M 10-Q · filed 2021-05-17 | -$13.89M derived: sum of 2 quarters · filed 2021-05-17 | -$21.45M derived: sum of 3 quarters · filed 2021-05-17 | -$38.17M derived: sum of 4 quarters · filed 2021-05-17 | ||||
| 2019-12-31 | -$5.96M derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-31 | -$13.51M derived: sum of 2 quarters · filed 2021-03-31 | -$30.23M derived: sum of 3 quarters · filed 2021-03-31 | -$38.54M 10-K · filed 2021-03-31 | -$38.54M 10-K · filed 2020-04-03 | |||
| 2019-09-30 | -$7.55M 10-Q · filed 2020-11-16 | -$7.56M 10-Q · filed 2019-11-14 | -$24.28M derived: sum of 2 quarters · filed 2020-11-16 | -$32.58M 10-Q · filed 2020-11-16 | -$32.58M 10-Q · filed 2019-11-14 | -$45.23M derived: sum of 4 quarters · filed 2020-11-16 | ||
| 2019-06-30 | -$16.72M 10-Q · filed 2020-08-13 | -$16.72M 10-Q · filed 2019-08-14 | -$25.02M 10-Q · filed 2020-08-13 | -$25.02M 10-Q · filed 2019-08-14 | -$37.68M derived: sum of 3 quarters · filed 2020-08-13 | -$43.82M derived: sum of 4 quarters · filed 2020-08-13 | ||
| 2019-03-31 | -$8.30M 10-Q · filed 2020-05-15 | -$8.30M 10-Q · filed 2019-05-21 | -$20.96M derived: sum of 2 quarters · filed 2020-05-15 | -$27.10M derived: sum of 3 quarters · filed 2020-05-15 | -$34.75M derived: sum of 4 quarters · filed 2020-05-15 | |||
| 2018-12-31 | -$12.65M derived: 10-K 12 month − 10-Q 9 month · filed 2020-04-03 | -$18.79M derived: sum of 2 quarters · filed 2020-04-03 | -$26.45M derived: sum of 3 quarters · filed 2020-04-03 | -$32.15M 10-K · filed 2020-04-03 | ||||
| 2018-09-30 | -$6.14M 10-Q · filed 2019-11-14 | -$13.80M derived: sum of 2 quarters · filed 2019-11-14 | -$19.49M 10-Q · filed 2019-11-14 | -$39.70M derived: sum of 4 quarters · filed 2019-11-14 | ||||
| 2018-06-30 | -$7.66M 10-Q · filed 2019-08-14 | -$13.35M 10-Q · filed 2019-08-14 | -$33.56M derived: sum of 3 quarters · filed 2019-08-14 | -$28.80M derived: sum of 4 quarters · filed 2019-08-14 | ||||
| 2018-03-31 | -$5.70M 10-Q · filed 2019-05-21 | -$25.90M derived: sum of 2 quarters · filed 2019-05-21 | -$21.14M derived: sum of 3 quarters · filed 2019-05-21 | -$22.95M derived: sum of 4 quarters · filed 2019-05-21 | ||||
| 2017-12-31 | -$20.21M derived: 10-K 12 month − 10-Q 9 month · filed 2019-04-10 | -$15.45M derived: sum of 2 quarters · filed 2019-04-10 | -$17.25M derived: sum of 3 quarters · filed 2019-04-10 | -$21.97M 10-K · filed 2019-04-10 | ||||
| 2017-09-30 | $4.76M 10-Q · filed 2018-11-19 | $2.95M derived: sum of 2 quarters · filed 2018-11-19 | -$1.76M 10-Q · filed 2018-11-19 | -$5.44M derived: sum of 4 quarters · filed 2018-11-19 | ||||
| 2017-06-30 | -$1.81M 10-Q · filed 2018-08-13 | -$6.52M 10-Q · filed 2018-08-13 | -$10.20M derived: sum of 3 quarters · filed 2018-08-13 | -$13.61M derived: sum of 4 quarters · filed 2018-08-13 | ||||
| 2017-03-31 | -$4.72M 10-Q · filed 2018-05-15 | -$8.39M derived: sum of 2 quarters · filed 2018-05-15 | -$11.81M derived: sum of 3 quarters · filed 2018-05-15 | -$15.46M derived: sum of 4 quarters · filed 2018-05-15 | ||||
| 2016-12-31 | -$3.68M derived: 10-K 12 month − 10-Q 9 month · filed 2018-04-09 | -$7.09M derived: sum of 2 quarters · filed 2018-04-09 | -$10.75M derived: sum of 3 quarters · filed 2018-04-09 | -$14.73M 10-K · filed 2018-04-09 | ||||
| 2016-09-30 | -$3.42M 10-Q · filed 2017-11-20 | -$7.07M derived: sum of 2 quarters · filed 2017-11-20 | -$11.06M 10-Q · filed 2017-11-20 | -$15.19M derived: sum of 4 quarters · filed 2017-11-20 | ||||
| 2016-06-30 | -$3.66M 10-Q · filed 2017-08-09 | -$7.64M 10-Q · filed 2017-08-09 | -$11.77M derived: sum of 3 quarters · filed 2017-08-09 | -$14.73M derived: sum of 4 quarters · filed 2017-08-09 | ||||
| 2016-03-31 | -$3.98M 10-Q/A · filed 2017-06-23 | -$8.12M derived: sum of 2 quarters · filed 2017-06-23 | -$11.08M derived: sum of 3 quarters · filed 2017-06-23 | -$16.34M derived: sum of 4 quarters · filed 2017-06-23 | ||||
| 2015-12-31 | -$4.13M derived: 10-K 12 month − 10-Q 9 month · filed 2017-02-15 | -$7.09M derived: sum of 2 quarters · filed 2017-02-15 | -$12.35M derived: sum of 3 quarters · filed 2017-02-15 | -$16.29M 10-K · filed 2017-02-15 | ||||
| 2015-09-30 | -$2.96M 10-Q · filed 2016-11-14 | -$8.22M derived: sum of 2 quarters · filed 2016-11-14 | -$12.16M 10-Q · filed 2016-11-14 | -$14.13M derived: sum of 4 quarters · filed 2016-11-14 | ||||
| 2015-06-30 | -$5.26M 10-Q · filed 2016-08-15 | -$9.20M 10-Q · filed 2016-08-15 | -$11.17M derived: sum of 3 quarters · filed 2016-08-15 | -$13.90M derived: sum of 4 quarters · filed 2016-08-15 | ||||
| 2015-03-31 | -$3.94M 10-Q · filed 2016-05-10 | -$5.91M derived: sum of 2 quarters · filed 2016-05-10 | -$8.64M derived: sum of 3 quarters · filed 2016-05-10 | -$10.58M derived: sum of 4 quarters · filed 2016-05-10 | ||||
| 2014-12-31 | -$1.97M derived: 10-K 12 month − 10-Q 9 month · filed 2016-03-29 | -$4.70M derived: sum of 2 quarters · filed 2016-03-29 | -$6.64M derived: sum of 3 quarters · filed 2016-03-29 | -$8.61M 10-K · filed 2016-03-29 | ||||
| 2014-09-30 | -$2.73M 10-Q · filed 2015-11-13 | -$4.67M derived: sum of 2 quarters · filed 2015-11-13 | -$6.64M 10-Q · filed 2015-11-13 | |||||
| 2014-06-30 | -$1.94M 10-Q · filed 2015-08-13 | -$3.91M 10-Q · filed 2015-08-13 | ||||||
| 2014-03-31 | -$1.97M 10-Q · filed 2015-06-26 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Latigo Biotherapeutics, Inc. (LTGO) | United States | $1.176B | |
| LB PHARMACEUTICALS INC (LBRX) | United States | $1.220B | -10.87 |
| OPKO HEALTH, INC. (OPK) | United States | $1.220B | -15.59 |
| Seaport Therapeutics, Inc. (SPTX) | United States | $1.131B | |
| HARROW, INC. (HROW) | United States | $1.240B | -42.77 |
| Damora Therapeutics, Inc. (DMRA) | $1.250B | -6.10 | |
| Amphastar Pharmaceuticals, Inc. (AMPH) | United States | $1.116B | 10.93 |
| Avalyn Pharma Inc. (AVLN) | United States | $1.267B | |
| First Tracks Biotherapeutics, Inc. (TRAX) | United States | $1.280B | |
| Alto Neuroscience, Inc. (ANRO) | United States | $1.065B | -11.02 |